Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy before surgery improves outcomes for women with a specific type of breast cancer that is hormone receptor-positive (HR+) and HER2-negative. This approach — giving treatment before surgery to shrink the tumor — is called neoadjuvant therapy. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have been diagnosed with invasive HR+/HER2- breast cancer with a tumor larger than 1 cm - Your cancer has not spread to distant parts of the body - You are in generally good physical health (ECOG score 0–1) **You may NOT be eligible if...** - You have already received chemotherapy or hormone therapy for this cancer - You have a serious autoimmune condition or are on immune-suppressing medications - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.